Literature DB >> 11505081

Quantitation of the factor VII- and single-chain plasminogen activator-activating protease in plasmas of healthy subjects.

J Römisch1, A Feussner, H A Stöhr.   

Abstract

Plasma samples of 189 healthy subjects were investigated for antigen levels of the recently reported factor VII- and single-chain plasminogen activator-activating protease (FSAP) and the corresponding pro-urokinase activating potencies. While the age of donors had no significant effect on the investigated parameters, female plasmas revealed a trend to higher antigen contents and activity levels. Surprisingly, as much as 9% of all samples contained significantly reduced single-chain urinary plasminogen activator activating potential, whereas antigen concentrations were normal. Additionally, 1% of the plasmas was found to decrease in both FSAP antigen and activity contents. FSAP of three subjects displaying reduced activities throughout a follow-up period of 6 months were purified from plasmas and were characterized. As compared with pool plasma derived FSAP, investigation of the individual preparations confirmed their reduced potency to activate pro-urokinase. However, factor VII activation was not affected. It is speculated that the FSAP binding site for single-chain plasminogen activators is affected, potentially by as yet unknown polymorphism(s) or mutation(s).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505081     DOI: 10.1097/00001721-200107000-00007

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Transforming Growth Factor-β (TGF-β) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes.

Authors:  Silke Leiting; Sebastian Seidl; Adoracion Martinez-Palacian; Lars Muhl; Sandip M Kanse
Journal:  J Biol Chem       Date:  2016-07-26       Impact factor: 5.157

2.  Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS).

Authors:  Malgorzata Wygrecka; Philipp Markart; Ludger Fink; Andreas Guenther; Klaus T Preissner
Journal:  Thorax       Date:  2007-05-04       Impact factor: 9.139

3.  Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study.

Authors:  Mariana S Parahuleva; Sandip Kanse; Hans Hölschermann; Kirila Zheleva; Daniel Zandt; Michael Worsch; Behnoush Parviz; Norbert Güttler; Harald Tillmanns; Andreas Böning; Ali Erdogan
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

4.  The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation.

Authors:  Daniel Sedding; Jan-Marcus Daniel; Lars Muhl; Karin Hersemeyer; Hannes Brunsch; Bettina Kemkes-Matthes; Ruediger C Braun-Dullaeus; Harald Tillmanns; Thomas Weimer; Klaus T Preissner; Sandip M Kanse
Journal:  J Exp Med       Date:  2006-12-04       Impact factor: 14.307

5.  Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity.

Authors:  M Olsson; T M Stanne; A Pedersen; E Lorentzen; E Kara; A Martinez-Palacian; N P Rønnow Sand; A F Jacobsen; P M Sandset; J J Sidelmann; G Engström; O Melander; S M Kanse; C Jern
Journal:  J Thromb Haemost       Date:  2018-08-24       Impact factor: 5.824

6.  Factor VII Activating Protease Expression in Human Platelets and Accumulation in Symptomatic Carotid Plaque.

Authors:  Mariana S Parahuleva; Michael Worsch; Gerhild Euler; Maryana Choukeir; Amar Mardini; Behnoush Parviz; Sandip M Kanse; Irene Portig; Evgeny Khayrutdinov; Bernhard Schieffer; Birgit Markus
Journal:  J Am Heart Assoc       Date:  2020-08-28       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.